Sunshine Biopharma, Inc. (SBFM)
USD 2.75
(0.37%)
USD 2.75
(0.37%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -4.5 Million USD | 83.15% |
| 2022 | -26.74 Million USD | -109.51% |
| 2021 | -12.76 Million USD | -1322.02% |
| 2020 | -897.68 Thousand USD | 38.58% |
| 2019 | -1.46 Million USD | 32.22% |
| 2018 | -2.15 Million USD | -107.28% |
| 2017 | -1.04 Million USD | 70.25% |
| 2016 | -3.49 Million USD | -111.55% |
| 2015 | -1.65 Million USD | 14.54% |
| 2014 | -1.93 Million USD | 22.37% |
| 2013 | -2.49 Million USD | -251.93% |
| 2012 | -707.95 Thousand USD | -27.28% |
| 2011 | -556.2 Thousand USD | -3.5% |
| 2010 | -537.38 Thousand USD | 0.0% |
| 2009 | - USD | 100.0% |
| 2008 | -31.1 Thousand USD | -137.04% |
| 2007 | -13.12 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -494.3 Thousand USD | 61.5% |
| 2024 Q1 | -1.28 Million USD | -2.7% |
| 2023 Q3 | -651.48 Thousand USD | 27.78% |
| 2023 Q1 | -1.7 Million USD | 92.76% |
| 2023 Q2 | -902.1 Thousand USD | 47.01% |
| 2023 Q4 | -1.25 Million USD | -91.87% |
| 2023 FY | -4.5 Million USD | 83.15% |
| 2022 Q4 | -23.51 Million USD | -1513.76% |
| 2022 Q2 | -381.94 Thousand USD | 69.1% |
| 2022 FY | -26.74 Million USD | -109.51% |
| 2022 Q1 | -1.23 Million USD | -285.31% |
| 2022 Q3 | -1.45 Million USD | -281.46% |
| 2021 Q3 | -4.03 Million USD | -40.3% |
| 2021 Q1 | -6.18 Million USD | -470.69% |
| 2021 Q4 | 667.11 Thousand USD | 116.52% |
| 2021 Q2 | -2.87 Million USD | 53.45% |
| 2021 FY | -12.76 Million USD | -1322.02% |
| 2020 FY | -897.68 Thousand USD | 38.58% |
| 2020 Q4 | -1.08 Million USD | -55.14% |
| 2020 Q2 | -638.31 Thousand USD | -577.19% |
| 2020 Q3 | -698.59 Thousand USD | -9.44% |
| 2020 Q1 | -94.25 Thousand USD | 76.23% |
| 2019 FY | -1.46 Million USD | 32.22% |
| 2019 Q1 | -202.54 Thousand USD | 40.19% |
| 2019 Q2 | -710.89 Thousand USD | -250.98% |
| 2019 Q3 | -350.24 Thousand USD | 50.73% |
| 2019 Q4 | -396.61 Thousand USD | -13.24% |
| 2018 FY | -2.15 Million USD | -107.28% |
| 2018 Q4 | -338.65 Thousand USD | 62.68% |
| 2018 Q3 | -907.55 Thousand USD | -40.86% |
| 2018 Q2 | -644.3 Thousand USD | -142.55% |
| 2018 Q1 | -265.63 Thousand USD | -25.61% |
| 2017 Q4 | -211.47 Thousand USD | -43.27% |
| 2017 Q3 | -147.61 Thousand USD | 69.59% |
| 2017 Q2 | -485.44 Thousand USD | -148.05% |
| 2017 Q1 | -195.7 Thousand USD | 82.6% |
| 2017 FY | -1.04 Million USD | 70.25% |
| 2016 Q4 | -1.12 Million USD | 29.08% |
| 2016 FY | -3.49 Million USD | -111.55% |
| 2016 Q3 | -1.58 Million USD | -229.44% |
| 2016 Q2 | -481.31 Thousand USD | -57.65% |
| 2016 Q1 | -305.29 Thousand USD | 52.86% |
| 2015 Q2 | -517.51 Thousand USD | -75.81% |
| 2015 Q3 | -202.81 Thousand USD | 60.81% |
| 2015 Q4 | -647.67 Thousand USD | -219.34% |
| 2015 FY | -1.65 Million USD | 14.54% |
| 2015 Q1 | -294.36 Thousand USD | 11.79% |
| 2014 Q3 | -280.84 Thousand USD | 65.68% |
| 2014 FY | -1.93 Million USD | 22.37% |
| 2014 Q2 | -818.38 Thousand USD | -63.27% |
| 2014 Q4 | -333.71 Thousand USD | -18.82% |
| 2014 Q1 | -501.25 Thousand USD | 26.91% |
| 2013 Q2 | -152.96 Thousand USD | 89.64% |
| 2013 Q1 | -1.47 Million USD | -682.55% |
| 2013 Q4 | -685.78 Thousand USD | -285.15% |
| 2013 FY | -2.49 Million USD | -251.93% |
| 2013 Q3 | -178.05 Thousand USD | -16.4% |
| 2012 Q3 | -376.78 Thousand USD | -265.57% |
| 2012 Q2 | -103.06 Thousand USD | -161.98% |
| 2012 Q4 | -188.76 Thousand USD | 49.9% |
| 2012 Q1 | -39.34 Thousand USD | 89.43% |
| 2012 FY | -707.95 Thousand USD | -27.28% |
| 2011 Q4 | -372.05 Thousand USD | -219.52% |
| 2011 Q3 | -116.44 Thousand USD | -606.13% |
| 2011 Q1 | -49.21 Thousand USD | 86.94% |
| 2011 FY | -556.2 Thousand USD | -3.5% |
| 2011 Q2 | -16.49 Thousand USD | 66.49% |
| 2010 Q2 | -1.58 Million USD | -1776.05% |
| 2010 Q4 | -376.94 Thousand USD | -124.93% |
| 2010 FY | -537.38 Thousand USD | 0.0% |
| 2010 Q3 | 1.51 Million USD | 195.23% |
| 2010 Q1 | -84.64 Thousand USD | 0.0% |
| 2009 FY | - USD | 100.0% |
| 2009 Q3 | -1.13 Million USD | -12826.41% |
| 2009 Q2 | -8766.00 USD | -49.11% |
| 2009 Q1 | -5879.00 USD | -55.0% |
| 2008 Q3 | -6578.00 USD | -16.82% |
| 2008 Q4 | -3793.00 USD | 42.34% |
| 2008 FY | -31.1 Thousand USD | -137.04% |
| 2008 Q1 | -14.42 Thousand USD | -536.64% |
| 2008 Q2 | -5631.00 USD | 60.95% |
| 2007 Q4 | -2265.00 USD | 74.23% |
| 2007 FY | -13.12 Thousand USD | 0.0% |
| 2007 Q3 | -8788.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Theratechnologies Inc. | -23.95 Million USD | 81.191% |
| Harrow Health, Inc. | -24.41 Million USD | 81.541% |
| Dynavax Technologies Corporation | -6.38 Million USD | 29.472% |
| Biofrontera Inc. | -20.13 Million USD | 77.616% |
| Cronos Group Inc. | -73.96 Million USD | 93.908% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 6.804% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 99.55% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 89.322% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 118.841% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 28.24% |
| Radius Health, Inc. | -25.79 Million USD | 82.529% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 26.886% |
| DURECT Corporation | -27.62 Million USD | 83.688% |
| ProPhase Labs, Inc. | -16.78 Million USD | 73.15% |
| Safety Shot Inc | -15.08 Million USD | 70.125% |
| Phibro Animal Health Corporation | 2.41 Million USD | 286.508% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -45.425% |
| Alvotech | -551.73 Million USD | 99.183% |
| Assertio Holdings, Inc. | -331.94 Million USD | 98.643% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 442.405% |
| Rockwell Medical, Inc. | -8.43 Million USD | 46.605% |
| Procaps Group S.A. | 42.54 Million USD | 110.592% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 96.774% |
| SCYNEXIS, Inc. | 67.04 Million USD | 106.721% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 71.56% |
| Viatris Inc. | 54.7 Million USD | 108.238% |
| OptiNose, Inc. | -35.48 Million USD | 87.301% |
| SIGA Technologies, Inc. | 68.06 Million USD | 106.62% |
| Tilray Brands, Inc. | -244.98 Million USD | 98.161% |
| PetIQ, Inc. | 2.13 Million USD | 311.452% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -0.0% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 101.805% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 2951.331% |
| Alimera Sciences, Inc. | -20.13 Million USD | 77.618% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 109.357% |
| Silver Spike Investment Corp. | 7.34 Million USD | 161.389% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 31.651% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 191.123% |
| Journey Medical Corporation | -3.85 Million USD | -16.949% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 44.8% |
| Alpha Teknova, Inc. | -36.78 Million USD | 87.749% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 74.825% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 137.51% |
| PainReform Ltd. | -9.34 Million USD | 51.776% |
| Cosmos Health Inc. | -18.54 Million USD | 75.699% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 97.189% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 56.158% |
| Embecta Corp. | 70.4 Million USD | 106.401% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -4.747% |
| Talphera, Inc. | -18.39 Million USD | 75.507% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 110.74% |
| Incannex Healthcare Limited | -18.45 Million USD | 75.589% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 77.534% |
| Shineco, Inc. | -22.44 Million USD | 79.928% |
| Procaps Group, S.A. | 42.54 Million USD | 110.592% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 123.995% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 42.744% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 101.379% |
| Alvotech | -551.73 Million USD | 99.183% |
| Hempacco Co., Inc. | -13.12 Million USD | 65.671% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 112.643% |
| Bright Green Corporation | -13.12 Million USD | 65.675% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 97.847% |
| Kamada Ltd. | 8.28 Million USD | 154.395% |
| Indivior PLC | 2 Million USD | 325.302% |
| Evoke Pharma, Inc. | -7.79 Million USD | 42.173% |
| Flora Growth Corp. | -57.03 Million USD | 92.1% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 77.534% |
| Evolus, Inc. | -61.68 Million USD | 92.695% |
| HUTCHMED (China) Limited | 100.78 Million USD | 104.471% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 103.276% |
| Akanda Corp. | -32.27 Million USD | 86.039% |